Maho Iwamoto1, Kimitoshi Kato2, Mitsuhiko Moriyama3. 1. Department of Internal Medicine Division of Gastroenterology and Hepatology, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi-ku, Tokyo, 173-8610, Japan. maho_9245@yahoo.co.jp. 2. Division of Research Planning and Development, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi-ku, Tokyo, 173-8610, Japan. 3. Department of Internal Medicine Division of Gastroenterology and Hepatology, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Abstract
BACKGROUND: Crohn's disease is intractable and is frequently diagnosed in younger people. No clear policies exist regarding medical treatment for seniors with this disease, and its diagnosis and treatment are often hindered by difficulties attributable to comorbidities, complex differential diagnoses, and polypharmacy. We describe an elderly-onset Crohn's disease patient showing a marked remission-maintaining effect with no adverse events after administration of ustekinumab. METHODS AND RESULTS: A 75-year-old patient with Crohn's disease and a history of pulmonary tuberculosis had first presented to our hospital at age 64 years and was hospitalized. Based on physical examinations, colonoscopy, and blood test results, Crohn's disease was diagnosed. The patient experienced secondary losses of responsiveness to two tumor necrosis factor (TNF)-alpha inhibitors, and after repeated hospital admissions, she was administered ustekinumab. The patient's symptoms, endoscopic findings, Crohn's Disease Activity Index, serum albumin, and physical activity levels improved markedly, and disease remission has been maintained for 2 years to date. CONCLUSION: Ustekinumab is an effective treatment option for elderly patients with intractable Crohn's disease when TNF-alpha inhibitors are ineffective.
BACKGROUND:Crohn's disease is intractable and is frequently diagnosed in younger people. No clear policies exist regarding medical treatment for seniors with this disease, and its diagnosis and treatment are often hindered by difficulties attributable to comorbidities, complex differential diagnoses, and polypharmacy. We describe an elderly-onset Crohn's diseasepatient showing a marked remission-maintaining effect with no adverse events after administration of ustekinumab. METHODS AND RESULTS: A 75-year-old patient with Crohn's disease and a history of pulmonary tuberculosis had first presented to our hospital at age 64 years and was hospitalized. Based on physical examinations, colonoscopy, and blood test results, Crohn's disease was diagnosed. The patient experienced secondary losses of responsiveness to two tumor necrosis factor (TNF)-alpha inhibitors, and after repeated hospital admissions, she was administered ustekinumab. The patient's symptoms, endoscopic findings, Crohn's Disease Activity Index, serum albumin, and physical activity levels improved markedly, and disease remission has been maintained for 2 years to date. CONCLUSION: Ustekinumab is an effective treatment option for elderly patients with intractable Crohn's disease when TNF-alpha inhibitors are ineffective.
Authors: Stephen B Hanauer; William J Sandborn; Brian G Feagan; Christopher Gasink; Douglas Jacobstein; Bin Zou; Jewel Johanns; Omoniyi J Adedokun; Bruce E Sands; Paul Rutgeerts; Willem J S de Villiers; Jean-Frédéric Colombel; Subrata Ghosh Journal: J Crohns Colitis Date: 2020-01-01 Impact factor: 9.071
Authors: Murat Toruner; Edward V Loftus; W Scott Harmsen; Alan R Zinsmeister; Robert Orenstein; William J Sandborn; Jean-Frederic Colombel; Laurence J Egan Journal: Gastroenterology Date: 2008-01-11 Impact factor: 22.682
Authors: Brian G Feagan; William J Sandborn; Christopher Gasink; Douglas Jacobstein; Yinghua Lang; Joshua R Friedman; Marion A Blank; Jewel Johanns; Long-Long Gao; Ye Miao; Omoniyi J Adedokun; Bruce E Sands; Stephen B Hanauer; Severine Vermeire; Stephan Targan; Subrata Ghosh; Willem J de Villiers; Jean-Frédéric Colombel; Zsolt Tulassay; Ursula Seidler; Bruce A Salzberg; Pierre Desreumaux; Scott D Lee; Edward V Loftus; Levinus A Dieleman; Seymour Katz; Paul Rutgeerts Journal: N Engl J Med Date: 2016-11-17 Impact factor: 91.245
Authors: Laura Lorenzo-López; Ana Maseda; Carmen de Labra; Laura Regueiro-Folgueira; José L Rodríguez-Villamil; José C Millán-Calenti Journal: BMC Geriatr Date: 2017-05-15 Impact factor: 3.921
Authors: W J Sandborn; P Rutgeerts; C Gasink; D Jacobstein; B Zou; J Johanns; B E Sands; S B Hanauer; S Targan; S Ghosh; W J S de Villiers; J-F Colombel; B G Feagan Journal: Aliment Pharmacol Ther Date: 2018-05-24 Impact factor: 8.171